Due to their involvement as checkpoints in immune cell responses, Sialic-acid-binding ImmunoGlobulin-like Lectins (Siglecs) have gained more and more interest as therapeutic targets in Immuno-Oncology and Immune regulation. You’ll be interested to learn that BPS Bioscience have developed and released a number of Siglec proteins and stable cell lines, which you can obtain in Europe through tebu-bio.

Developing new therapeutic agents to boost the immune system and avoid the escape of diseased cells from the natural defenses is the common goal of all researchers in Immunotherapy. To greatly reduce time and cost associated with this development in Immunotherapy research, BPS Bioscience have developed a complete tool box of efficient and validated assays.

Personalized treatment for cancer reached a new milestone with the FDA approval of CAR T-cells for treatment of leukemia and lymphoma.  There is now rapid growth in research on the therapeutic uses of CAR T-cells.

To help researchers develop efficient CAR T-cells, we aim to provide many innovative solutions, such as recombinant cell line expressing cancer antigens, or recombinant versions of these antigens. Developed by BPS Bioscience, these products will help scientists to more precisely monitor the effectiveness of the engineered CAR T to detect and bind to a specific cancer antigen.

For many pathologies such as cancer or neurological disorders, it has been found that Histone Deacetylase (HDAC) activity is disrupted, making them promising targets for drug development. Scientists need access to a broade range of products ( Active Enzyme, inhibitors/activators, Biochemical screening assays…), to simplify their research and identification of HDAC inhibitors.